Literature DB >> 12803925

Enzyme replacement therapy: conception, chaos and culmination.

Roscoe O Brady1.   

Abstract

Soon after the enzymatic defects in Gaucher disease and in Niemann-Pick disease were discovered, enzyme replacement or enzyme supplementation was proposed as specific treatment for patients with these and related metabolic storage disorders. While relatively straightforward in concept, successful implementation of this approach required many years of intensive effort to bring it to fruition. Procedures were eventually developed to produce sufficient quantities of the requisite enzymes for clinical trials and to target therapeutic enzymes to lipid-storing cells. These achievements led to the development of effective enzyme replacement therapy for patients with Gaucher disease and for Fabry disease. These demonstrations provide strong incentive for the application of this strategy for the treatment of many human disorders of metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12803925      PMCID: PMC1693186          DOI: 10.1098/rstb.2003.1269

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  38 in total

1.  Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease.

Authors:  R O Brady; P G Pentchev; A E Gal; S R Hibbert; A S Dekaban
Journal:  N Engl J Med       Date:  1974-11-07       Impact factor: 91.245

2.  Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease.

Authors:  R O Brady; J F Tallman; W G Johnson; A E Gal; W R Leahy; J M Quirk; A S Dekaban
Journal:  N Engl J Med       Date:  1973-07-05       Impact factor: 91.245

3.  Isolation and characterization of glucocerebrosidase from human placental tissue.

Authors:  P G Pentchev; R O Brady; S R Hibbert; A E Gal; D Shapiro
Journal:  J Biol Chem       Date:  1973-08-10       Impact factor: 5.157

4.  Identification of heterozygous carriers of lipid storage diseases. Current status and clinical applications.

Authors:  R O Brady; W G Johnson; B W Uhlendorf
Journal:  Am J Med       Date:  1971-10       Impact factor: 4.965

5.  Demonstration of an alteration of ganglioside metabolism in Tay-Sachs disease.

Authors:  E H Kolodny; R O Brady; B W Volk
Journal:  Biochem Biophys Res Commun       Date:  1969-10-22       Impact factor: 3.575

6.  Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease.

Authors:  R O Brady; J N Kanfer; R M Bradley; D Shapiro
Journal:  J Clin Invest       Date:  1966-07       Impact factor: 14.808

7.  Lysosomal hydrolases as glycoproteins.

Authors:  A Goldstone; H Koenig
Journal:  Life Sci II       Date:  1970-12-08

8.  Fabry's disease: antenatal detection.

Authors:  R O Brady; B W Uhlendorf; C B Jacobson
Journal:  Science       Date:  1971-04-09       Impact factor: 47.728

9.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

Authors:  R O Brady; A E Gal; R M Bradley; E Martensson; A L Warshaw; L Laster
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

10.  The metabolism of Tay-Sachs ganglioside: catabolic studies with lysosomal enzymes from normal and Tay-Sachs brain tissue.

Authors:  J F Tallman; W G Johnson; R O Brady
Journal:  J Clin Invest       Date:  1972-09       Impact factor: 14.808

View more
  26 in total

1.  Blood to brain to the rescue.

Authors:  Richard L Proia; Yun-Ping Wu
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 2.  New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 Mar-Apr

3.  Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Drug Deliv Transl Res       Date:  2012-06-01       Impact factor: 4.617

4.  Ectopic expression of a conifer Abscisic Acid Insensitive3 transcription factor induces high-level synthesis of recombinant human alpha-L-iduronidase in transgenic tobacco leaves.

Authors:  Allison R Kermode; Ying Zeng; Xiaoke Hu; Samantha Lauson; Suzanne R Abrams; Xu He
Journal:  Plant Mol Biol       Date:  2007-01-04       Impact factor: 4.076

Review 5.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

Review 6.  Emptying the stores: lysosomal diseases and therapeutic strategies.

Authors:  Frances M Platt
Journal:  Nat Rev Drug Discov       Date:  2017-11-17       Impact factor: 84.694

7.  Genetic counseling throughout the life cycle.

Authors:  Leslie J Ciarleglio; Robin L Bennett; Jennifer Williamson; Jessica B Mandell; Joan H Marks
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

8.  Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses.

Authors:  Fredj Ben Bdira; Marta Artola; Herman S Overkleeft; Marcellus Ubbink; Johannes M F G Aerts
Journal:  J Lipid Res       Date:  2018-10-02       Impact factor: 5.922

9.  Catalytic mechanism of human alpha-galactosidase.

Authors:  Abigail I Guce; Nathaniel E Clark; Eric N Salgado; Dina R Ivanen; Anna A Kulminskaya; Harry Brumer; Scott C Garman
Journal:  J Biol Chem       Date:  2009-11-25       Impact factor: 5.157

10.  Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.

Authors:  Jason Papademetriou; Carmen Garnacho; Daniel Serrano; Tridib Bhowmick; Edward H Schuchman; Silvia Muro
Journal:  J Inherit Metab Dis       Date:  2012-09-12       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.